Skip to main content

ORIGINAL RESEARCH article

Front. Cardiovasc. Med.
Sec. General Cardiovascular Medicine
Volume 12 - 2025 | doi: 10.3389/fcvm.2025.1518022
This article is part of the Research Topic The Right Heart: A Key Target for Cardiovascular Medicine View all 5 articles

Circulating miRNA-486 as a novel diagnostic biomarker for right ventricular remodeling

Provisionally accepted
Huiling Cai Huiling Cai 1,2*Yu Cheng Yu Cheng 3Xiuchuan Li Xiuchuan Li 2*Xuenan Wang Xuenan Wang 1,2*Yongjian Yang Yongjian Yang 1,2,4*Cong Lan Cong Lan 2,4*
  • 1 Department of Clinical Medicine, Southwest Medical University, Luzhou, Sichuan Province, China
  • 2 Department of Cardiovascular Medicine, Western Theater General Hospital, Chengdu, Sichuan Province, China
  • 3 Department of Cardiology, Fujian Heart Center, Provincial Institute of Coronary Disease, Fujian Medical University Union Hospital, Fuzhou, China
  • 4 College of Medicine, Southwest Jiaotong University, Chengdu, Sichuan Province, China

The final, formatted version of the article will be published soon.

    Objective Clinical practice currently faces a significant shortfall in specific biomarkers needed for diagnosing right ventricular (RV) remodeling in patients with pulmonary hypertension (PH). While small noncoding microRNAs (miRNAs) are crucial regulators of RV remodeling, the biomarker potential of serum miRNAs in this process is little known. This study systematically screened and identified candidate serum miRNAs as potential diagnostic biomarkers for RV remodeling in PH patients.Pulmonary artery banding (PAB) was performed in Sprague-Dawley (SD) rats and RV modeling was measured by echocardiographic and histological analyses 4 weeks after surgery. High-throughput miRNA sequencing of serum samples was performed to profile differentially-expressed miRNAs (dif-miRNAs) and preliminarily screen candidate miRNAs. The diagnostic power of the candidate miRNA was further validated in 100 patients (20 with adaptive RV pressure overload; 20 with maladaptive RV pressure overload; 20 with left heart failure (LHF); 19 with left ventricular hypertrophy and 21 controls).Results PAB rats exhibited severe RV hypertrophy, fibrosis and enlargement of RV cardiomyocytes compared with sham group. MiRNA sequencing analyses revealed 19 dif-miRNAs (12 upregulated and 7 downregulated) between the two groups. Among the 12 upregulated miRNAs, miRNA-486 exhibited highest elevation in PAB group and was supposed to be the candidate biomarker for RV modeling. Serum miRNA-486 levels were lower in control and left ventricular hypertrophy (LVH) patients compared to PH patients, and significantly higher in maladapted RV patients than in adapted RV patients. Serum miRNA-486 was significantly higher in LHF patients compared to controls, but still significantly lower than in PH patients. In receiver operating characteristic (ROC) analysis, serum miRNA-486 was a good predictor of RV maladaptation in PH patients (cut-off value 3.441, AUC 0.8625), which was not significantly different from B-type natriuretic peptide (BNP). Elevated serum miRNA-486 levels (≥3.441) were associated with reduced TAPSE/PASP ratios and increased BNP levels.Conclusions Serum miRNA-486 has the potential to be a valuable noninvasive biomarker for diagnosing RV remodeling in patients with PH.

    Keywords: miRNA-486, Diagnostic biomarker, pulmonary hypertension, Right ventricular remodeling, pulmonary artery banding

    Received: 27 Oct 2024; Accepted: 13 Jan 2025.

    Copyright: © 2025 Cai, Cheng, Li, Wang, Yang and Lan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Huiling Cai, Department of Clinical Medicine, Southwest Medical University, Luzhou, 646000, Sichuan Province, China
    Xiuchuan Li, Department of Cardiovascular Medicine, Western Theater General Hospital, Chengdu, Sichuan Province, China
    Xuenan Wang, Department of Clinical Medicine, Southwest Medical University, Luzhou, 646000, Sichuan Province, China
    Yongjian Yang, Department of Clinical Medicine, Southwest Medical University, Luzhou, 646000, Sichuan Province, China
    Cong Lan, Department of Cardiovascular Medicine, Western Theater General Hospital, Chengdu, Sichuan Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.